Total Payments
$91,508
2020 Payments
$150.00
Companies
2
Transactions
18
Payment Breakdown by Category
Research$88,862 (97.1%)
Travel$1,759 (1.9%)
Food & Beverage$886.70 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $88,862 | 12 | 97.1% |
| Travel and Lodging | $1,759 | 4 | 1.9% |
| Food and Beverage | $886.70 | 2 | 1.0% |
Payments by Type
Research
$88,862
12 transactions
General
$2,646
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $88,862 | 12 | $0 (2020) |
| Novo Nordisk AS | $2,646 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $150.00 | 1 | Eli Lilly and Company ($150.00) |
| 2019 | $3,860 | 2 | Eli Lilly and Company ($3,860) |
| 2018 | $55,796 | 6 | Eli Lilly and Company ($55,796) |
| 2017 | $31,702 | 9 | Eli Lilly and Company ($29,056) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $150.00 | Research |
| Study: A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | ||||||
| 01/15/2019 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $1,590.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 01/07/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,270.00 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | ||||||
| 12/28/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | Cash or cash equivalent | $2,586.45 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 03/15/2018 | Eli Lilly and Company | TRULICITY (Drug) | — | In-kind items and services | $2,975.44 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS • Category: Diabetes | ||||||
| 02/06/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,549.00 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | ||||||
| 02/02/2018 | Eli Lilly and Company | — | — | In-kind items and services | $6,407.78 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | ||||||
| 01/30/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $31,135.00 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | ||||||
| 01/08/2018 | Eli Lilly and Company | — | — | In-kind items and services | $3,141.85 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | ||||||
| 08/17/2017 | Novo Nordisk AS | FIASP (Drug) | Food and Beverage | In-kind items and services | $482.95 | General |
| Category: Diabetes | ||||||
| 08/17/2017 | Novo Nordisk AS | FIASP (Drug) | Travel and Lodging | In-kind items and services | $264.47 | General |
| Category: Diabetes | ||||||
| 06/20/2017 | Eli Lilly and Company | — | — | In-kind items and services | $9,618.34 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | ||||||
| 06/19/2017 | Eli Lilly and Company | — | — | In-kind items and services | $18,616.10 | Research |
| Study: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | ||||||
| 02/09/2017 | Eli Lilly and Company | TRULICITY (Drug) | — | In-kind items and services | $821.87 | Research |
| Study: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY • Category: Diabetes | ||||||
| 01/20/2017 | Novo Nordisk AS | Tresiba (Drug) | Travel and Lodging | In-kind items and services | $783.81 | General |
| Category: Diabetes | ||||||
| 01/20/2017 | Novo Nordisk AS | Tresiba (Drug) | Travel and Lodging | In-kind items and services | $404.18 | General |
| Category: Diabetes | ||||||
| 01/20/2017 | Novo Nordisk AS | Tresiba (Drug) | Food and Beverage | In-kind items and services | $403.75 | General |
| Category: Diabetes | ||||||
| 01/20/2017 | Novo Nordisk AS | Tresiba (Drug) | Travel and Lodging | In-kind items and services | $306.98 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $58,429 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $22,309 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $7,152 | 3 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $821.87 | 1 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $150.00 | 1 |
About Dr. Frank Mikell, M.D
Dr. Frank Mikell, M.D is a Specialist healthcare provider based in Springfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669582904.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Mikell, M.D has received a total of $91,508 in payments from pharmaceutical and medical device companies, with $150.00 received in 2020. These payments were reported across 18 transactions from 2 companies. The most common payment nature is "" ($88,862).
Ad
Practice Information
- Specialty Specialist
- Location Springfield, IL
- Active Since 08/30/2006
- Last Updated 06/02/2008
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1669582904
Products in Payments
- TRULICITY (Drug) $7,974
- Tresiba (Drug) $1,899
- FIASP (Drug) $747.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Springfield
Ziad Issa, M.d, M.D
Specialist — Payments: $168,793
Specialist $168,793
Dr. Michael Yunes
Specialist — Payments: $20,025
Specialist $20,025
Dr. Richard Anderson, M.d, M.D
Specialist — Payments: $15,773
Specialist $15,773
Dr. Leonard Ginsburg, M.d, M.D
Specialist — Payments: $13,791
Specialist $13,791
James Day, M.d, M.D
Specialist — Payments: $13,189
Specialist $13,189
James Mullin, M.d, M.D
Specialist — Payments: $12,899
Specialist $12,899